このページの読み込み中にエラーが発生したようです.
当社チームに通知しましたが、問題が続くようでしたらEメールサポートウィジェットを使ってご連絡ください。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 5.6x - 6.2x | 5.9x |
| Selected Fwd Revenue Multiple | 4.4x - 4.9x | 4.7x |
| Fair Value | ₩4,961 - ₩5,634 | ₩5,298 |
| Upside | 41.3% - 60.5% | 50.9% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| HansBiomed Corporation | A042520 | KOSDAQ:A042520 |
| Kangstem Biotech Co., Ltd. | A217730 | KOSDAQ:A217730 |
| KoBioLabs, Inc | A348150 | KOSDAQ:A348150 |
| Dx & Vx Co., Ltd. | A180400 | KOSDAQ:A180400 |
| Naturalendo Tech Co., Ltd. | A168330 | KOSDAQ:A168330 |
| CORESTEMCHEMON Inc. | A166480 | KOSDAQ:A166480 |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| A042520 | A217730 | A348150 | A180400 | A168330 | A166480 | |||
| KOSDAQ:A042520 | KOSDAQ:A217730 | KOSDAQ:A348150 | KOSDAQ:A180400 | KOSDAQ:A168330 | KOSDAQ:A166480 | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | 3.9% | 6.7% | 248.8% | 54.5% | 27.6% | 8.6% | ||
| 3Y CAGR | 11.1% | 11.6% | 93.3% | 82.5% | 14.9% | 8.5% | ||
| Latest Twelve Months | 3.0% | 30.3% | 109.2% | -2.6% | 18.5% | -29.5% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | -6.9% | -201.3% | -400.6% | -47.5% | -42.2% | -34.8% | ||
| Prior Fiscal Year | -5.3% | -126.1% | -174.8% | 8.2% | -21.8% | -13.8% | ||
| Latest Fiscal Year | 0.8% | -179.3% | -55.7% | -25.9% | -16.9% | -58.6% | ||
| Latest Twelve Months | -0.9% | -153.4% | -18.5% | -40.5% | -16.9% | -82.4% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 1.45x | 7.90x | 0.98x | 2.55x | 2.09x | 4.14x | ||
| EV / LTM EBIT | -158.6x | -5.2x | -5.3x | -6.3x | -12.3x | -5.0x | ||
| Price / LTM Sales | 1.13x | 9.92x | 1.41x | 2.14x | 2.03x | 2.93x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 0.98x | 2.09x | 7.90x | |||||
| Historical EV / LTM Revenue | 3.94x | 6.30x | 12.76x | |||||
| Selected EV / LTM Revenue | 5.60x | 5.90x | 6.19x | |||||
| (x) LTM Revenue | 28,884 | 28,884 | 28,884 | |||||
| (=) Implied Enterprise Value | 161,882 | 170,403 | 178,923 | |||||
| (-) Non-shareholder Claims * | (34,916) | (34,916) | (34,916) | |||||
| (=) Equity Value | 126,967 | 135,487 | 144,007 | |||||
| (/) Shares Outstanding | 24.4 | 24.4 | 24.4 | |||||
| Implied Value Range | 5,212.07 | 5,561.83 | 5,911.59 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 5,212.07 | 5,561.83 | 5,911.59 | 3,510.00 | ||||
| Upside / (Downside) | 48.5% | 58.5% | 68.4% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A042520 | A217730 | A348150 | A180400 | A168330 | A166480 | |
| Enterprise Value | 117,053 | 101,204 | 60,065 | 107,309 | 46,310 | 120,420 | |
| (+) Cash & Short Term Investments | 5,539 | 25,821 | 57,561 | 21,360 | 260 | 2,497 | |
| (+) Investments & Other | 5,118 | 7,548 | 2,498 | 9,318 | 872 | 3,679 | |
| (-) Debt | (36,398) | (7,610) | (16,503) | (40,964) | (2,908) | (41,091) | |
| (-) Other Liabilities | (13) | 0 | (17,314) | (6,854) | 332 | 0 | |
| (-) Preferred Stock | 0 | 0 | (94) | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 91,298 | 126,963 | 86,214 | 90,169 | 44,866 | 85,504 | |
| (/) Shares Outstanding | 13.0 | 56.1 | 19.4 | 49.2 | 31.6 | 24.4 | |
| Implied Stock Price | 7,030.00 | 2,265.00 | 4,450.00 | 1,832.00 | 1,421.00 | 3,510.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 7,030.00 | 2,265.00 | 4,450.00 | 1,832.00 | 1,421.00 | 3,510.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |